Pharmafile Logo

Decideum

Decideum has over 20 years experience in providing nuanced, effective and results-driven HTA and market access support to pharmaceutical clients in the UK and EU.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Genesis Research Group

Genesis Research Group empowers life science companies to innovate differently by fundamentally transforming the way they engage with research partners. Through the integration of robust stakeholder insights (RPR), data-agnostic expertise,…

View Profile

Havas Life London

We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by strategically aligning promotion, medical education and PR across the product…

View Profile

Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make a positive contribution to patient care. Real world experience of…

View Profile

Company Details

Niddry Lodge, 51 Holland Street, London, W8 7JB, United Kingdom
020 7368 1611

 Latest Content from PMHub 

Pharma need to keep their ‘pull & push’ separate from their ‘inbound & outbound’

Is your pharma brand using the marketing terms ‘pull & push’ correctly?

A man walks into a surgery: The role of storytelling in pharma marketing

Communicating through stories can make your brand messages more meaningful, memorable and persuasive

Embracing the demands of the empowered ‘consumer-savvy’ patient by Ann Generlich

Our access to information, which is now constantly at our fingertips and the explosion of new technologies has shifted the buying power to increasingly ‘consumer-savvy’ patients. These are patients who choose...

The Art of Agile Marketing

The industry knows that it needs become more responsive to its stakeholders. An agile approach – which quickly improves results through a process of rapid market feedback and response –...

Could ketamine be the next big thing in depression?

Account Executive Will Frostick discusses the established treatment model for depression and its limitations, as well as a new entrant poised to revolutionise the field – ketamine.

Attracting doctors to low-demand specialties: A role for industry?

 One of the major problems that healthcare systems around the world face is a paucity of medically qualified staff entering particular specialties and subspecialties. This can be due to a...

Men vs Women in emerging markets

Our latest interactive infographic compares male vs female health characteristics in the BRIC emerging marketS

South Korea: The next global player?

In this paper, we will explore some of the key trends and outlooks for South Korea in more detail, including what lies behind its presence at the extremes of two...

20 questions: Round 4

As it's our 20th year anniversary, we invited our employees to play our version of 20 questions - this month "What’s been the funniest thing to happen to you whilst you’ve...

Will gene therapies finally be commercially viable to pharma?

Our latest Free Thinking white paper explores the science behind the idea of gene therapy and takes a look at some of the core challenges medical researchers have faced when...